Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
This study has been completed.
Study NCT00136461   Information provided by Dana-Farber Cancer Institute

First Received on August 25, 2005.   Last Updated on March 9, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Precancerous Conditions
Interventions listed in this trial
All-trans retinoic acid
Bryostatin 1
Additional drug interventions recognized in this trial
Tretinoin
More general drug interventions related to this trial
Adjuvants, Immunologic
Antineoplastic Agents
Dermatologic Agents
Immunologic Factors
Keratolytic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Brigham and Women's Hospital


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services